Lawrence Steinman, MD
Neurology · Palo Alto
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- 18
- 4 carriers
- Office
- 1
On the public record
- Medicare does not list them as allowed to order and refer
Offices
1 location
Plans that list them
18 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Steinman’s office at (650) 498-5710 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
18 of 18 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G27574 · Current
Licensed to practise in California · since 1974 · expires 2027-11-30 · Harvard Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Medicaid work
$722 in 2024
Medicaid paid $722 for 18 billed services this clinician did in 2024, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE SF/LOW MDM 25 MINUTES | 18 | $722 |
| 2024 | 18 | 1 | 12 | $722 |
Money from drug and device companies
$128,020 in 2024
| 2024 | 4 | 4 | $128,020 | $128,020 |
| 2023 | 5 | 15 | $14,440 | $24,543 |
| 2022 | 6 | 9 | $38,750 | $40,174 |
| 2021 | 3 | 4 | $11,321 | $11,321 |
| 2020 | 2 | 7 | $13,462 | $16,071 |
| 2019 | 3 | 9 | $5,037 | $7,408 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Octapharma USA | Panzyga | $114,105 | 1 payment
|
| Sanofi Pasteur | None | $6,325 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | None | $4,800 | 1 payment
|
| Merck Sharp & Dohme | None | $2,790 | 1 payment
|
See all 4 published payments
| E.R. Squibb & Sons L.L.C. | Consulting · 2024-12-23 | None | $4,800 |
| Octapharma USA | Paid to speak or teach · 2024-06-12 | Panzyga | $114,105 |
| Sanofi Pasteur | Consulting · 2024-03-07 | None | $6,325 |
| Merck Sharp & Dohme | Consulting · 2024-02-12 | None | $2,790 |
See earlier years (2023, 2022, 2021, 2020, 2019)
2023: $24,543
| E.R. Squibb & Sons L.L.C. | Zeposia | $12,311 | 6 payments
|
| Merck Sharp & Dohme | None | $6,105 | 1 payment
|
| TG Therapeutics | Briumvi | $5,022 | 5 payments
|
| F. Hoffmann-La Roche AG | Ocrevus | $1,035 | 1 payment
|
| Celgene | Zeposia | $70 | 2 payments
|
2022: $40,174
| TG Therapeutics | None | $27,190 | 4 payments
|
| Exeltis USA | Purified Cortrophin Gel | $4,235 | 1 payment
|
| F. Hoffmann-La Roche AG | Ocrevus | $3,750 | 1 payment
|
| Regeneron Pharmaceuticals | None | $3,126 | 1 payment
|
| Biogen | Tecfidera | $1,839 | 1 payment
|
| EMD Serono | None | $35 | 1 payment
|
2021: $11,321
| Tg Therapeutics | None | $5,821 | 2 payments
|
| Celgene | Zeposia | $3,100 | 1 payment
|
| F. Hoffmann-La Roche AG | None | $2,400 | 1 payment
|
2020: $16,071
| Novartis Pharmaceuticals | None | $15,111 | 6 payments
|
| F. Hoffmann-La Roche AG | None | $960 | 1 payment
|
2019: $7,408
| Novartis Pharmaceuticals | Mayzent | $5,278 | 6 payments
|
| Celgene | Ozanimod | $2,103 | 2 payments
|
| Mallinckrodt Enterprises | Acthar | $27 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| F. Hoffmann-La Roche AG · High Dimensional Analysis of Brain, Lymph Nodes and Csf From Progressive Ms · 2022 | Their institution | $1,000,000 |
| F. Hoffmann-La Roche AG · High Dimensional Analysis of Brain, Lymph Nodes and Csf Applying Codex, Spatial Omics · 2024 | Their institution | $500,000 |
| F. Hoffmann-La Roche AG · Federated Learning: the Impact of Persistence on Clinical and Social Economic Outcomes in Multiple Sclerosis Treatments · 2025 | Their institution | $404,953 |
| F. Hoffmann-La Roche AG · High Dimensional Analysis of Brain, Lymph Nodes and Csf Applying Codex, Spatial ‘Omics’ · 2025 | Their institution | $323,207 |
| Genentech, Inc. · An Open-Label, Multicenter, Biomarker Study To Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Patients With Relapsing Multiple Sclerosis Or Primary Progressive Multiple Sclerosis · 2020 | Their institution | $113,502 |
| Genentech, Inc. · An Open-Label, Multicenter, Biomarker Study To Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Patients With Relapsing Multiple Sclerosis Or Primary Progressive Multiple Sclerosis · 2019 | Their institution | $104,784 |
| Retrophin, Inc. · 021fsgs16010 · 2019 | Their institution | $21,575 |
| TG THERAPEUTICS, INC. · 2022 | This clinician | $12,506 |
| Celgene Corporation · A Phase 2/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled (Part A) and Double-Blind, Double-Dummy, Active-Controlled (Part B), Parallel Group Study To Evaluate the Efficacy and Safety of Rpc1063 Administered Orally To Relapsing Multiple Sclerosis Patients (Rpc01-201) · 2019 | This clinician | $3,342 |
| TG Therapeutics, Inc. · Briumvi · 2025 | This clinician | $3,009 |
| Celgene Corporation · A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate the Efficacy and Safety of Rpc1063 Administered Orally To Relapsing Multiple Sclerosis Patients (Rpc01-301) · 2019 | This clinician | $2,866 |
| TG Therapeutics, Inc. · 2021 | This clinician | $2,531 |
| TG Therapeutics, Inc. · Briumvi · 2024 | This clinician | $2,442 |
Professional record
- NPI
- 1568507812
- Licence
- CA G27574California G27574: Current · expires 2027-11-30
More record details
- Sole proprietor
- No
- Taxonomy
- Neurology (2084N0400X)
- Mailing address
- 725 Welch Rd, Palo Alto, CA, 94304
- NPI first listed
- 2007-02-21
- NPI last updated
- 2023-11-07
- NPI record certified
- 2023-11-07
This is when the NPI record was last certified, not a medical board exam.